SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-23-000074
Filing Date
2023-08-09
Accepted
2023-08-09 08:03:52
Documents
14
Period of Report
2023-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20230809.htm   iXBRL 8-K 29852
2 EX-99.1 pressreleaseq2june2023.htm EX-99.1 84557
6 newlogo_09072021a.jpg GRAPHIC 17737
  Complete submission text file 0001599298-23-000074.txt   275800

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20230809.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20230809_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20230809_pre.xml EX-101.PRE 12512
8 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20230809_htm.xml XML 2736
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 231153436
SIC: 2834 Pharmaceutical Preparations